Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Blood

Retrieve available abstracts of 313 articles:
HTML format

Single Articles

    June 2023
  1. SLOAN SL, Brown F, Long ME, Weigel C, et al
    PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
    Blood. 2023 Jun 2:blood.2022019419. doi: 10.1182/blood.2022019419.
    PubMed     Abstract available

    Targeted therapy in mediastinal gray zone lymphoma.
    Blood. 2023;141:2673-2674.

    May 2023
  3. MEI M, Herrera AF
    The next frontier: enter PD-1 and exit PET scans?
    Blood. 2023;141:2545-2546.

  4. SACCO A, Desantis V, Celay J, Giustini V, et al
    Targeting the immune microenvironment in Waldenstrom macroglobulinemia via halting the CD40/CD40-ligand axis.
    Blood. 2023;141:2615-2628.
    PubMed     Abstract available

    How I treat older patients with DLBCL in the frontline setting.
    Blood. 2023;141:2566-2575.
    PubMed     Abstract available

  6. NICOLAY JP, Melchers S, Albrecht JD, Assaf C, et al
    Dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma - a multicenter phase II study.
    Blood. 2023 May 22:blood.2022018669. doi: 10.1182/blood.2022018669.
    PubMed     Abstract available

    A new CAR takes a test drive in DLBCL.
    Blood. 2023;141:2410-2411.

  8. YLSTRA B, de Jong D
    DNA or RNA? Classification of B-cell lymphomas.
    Blood. 2023;141:2413-2415.

    Putting the pedal to the metal: axi-cel for LBCL.
    Blood. 2023;141:2285-2286.

  10. CHABAY P
    Increasing microenvironment complexity in HL.
    Blood. 2023;141:2290-2291.

  11. BIGENWALD C, Zitvogel L
    Light shed from the gut in large B-cell lymphoma.
    Blood. 2023;141:2165-2166.

  12. BARTA SK
    Is it prime time for T-cell lymphoma?
    Blood. 2023;141:2161-2163.

  13. ZINZANI PLL, Thieblemont C, Melnichenko V, Bouabdallah K, et al
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.
    Blood. 2023 May 2:blood.2022019340. doi: 10.1182/blood.2022019340.
    PubMed     Abstract available

    April 2023
  14. JAYE DL, Feldman AL
    ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.
    Blood. 2023;141:2160.

  15. TOLU SS, Amengual JE
    Queen's gambit: response-adapted win in CAYA with cHL.
    Blood. 2023;141:2037-2038.

  16. DREVAL K, Hilton LK, Cruz M, Shaalan H, et al
    Genetic Subdivisions of Follicular Lymphoma Defined by Distinct Coding and non-coding Mutation Patterns.
    Blood. 2023 Apr 21:blood.2022018719. doi: 10.1182/blood.2022018719.
    PubMed     Abstract available

  17. ATTIEH M, Asakrah S
    Indolent NK-cell lymphoproliferative disorder of the GI tract: a rare indolent neoplasm of the GI tract.
    Blood. 2023;141:2033.

  18. SONG Y, Tilly H, Rai S, Zhang H, et al
    Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
    Blood. 2023;141:1971-1981.
    PubMed     Abstract available

  19. Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632-1644.
    Blood. 2023;141:1896.

  20. ATTIEH M, Asakrah S
    B-ALL with synchronous MYC and BCL-2 rearrangement.
    Blood. 2023;141:1894.

  21. BRANDSTOETTER T, Schmoellerl J, Grausenburger R, Kollmann S, et al
    SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
    Blood. 2023;141:1831-1845.
    PubMed     Abstract available

  22. SI LIM S, Ford JB, Hermiston ML
    How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
    Blood. 2023 Apr 5:blood.2022016503. doi: 10.1182/blood.2022016503.
    PubMed     Abstract available

    March 2023
  23. EERTINK JJ, Zwezerijnen GJ, Heymans M, Pieplenbosch S, et al
    Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
    Blood. 2023 Mar 31:blood.2022018558. doi: 10.1182/blood.2022018558.
    PubMed     Abstract available

  24. Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
    Blood. 2023;141:1647.

  25. Johnston RL, Mottok A, Chan FC, et al. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022;139(6):889-893.
    Blood. 2023;141:1495.

  26. ROZENOVA KA, Xiao W
    Primary thymic marginal zone lymphoma with amyloidosis.
    Blood. 2023;141:1494.

  27. STACHELSCHEID J, Jiang Q, Aszyk C, Warner K, et al
    The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
    Blood. 2023;141:1425-1441.
    PubMed     Abstract available

  28. FOX LC
    Unraveling family ties in Hodgkin lymphoma.
    Blood. 2023;141:1240-1241.

  29. BAYKARA Y, Kurt H
    Low-grade follicular lymphoma with extensive marginal zone differentiation and expression of MUM1 and CD30.
    Blood. 2023;141:1363.

  30. LYNCH RC, Ujjani CS, Poh C, Warren EH, et al
    Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.
    Blood. 2023 Mar 13:blood.2022019254. doi: 10.1182/blood.2022019254.
    PubMed     Abstract available

  31. CARBONE A, Gloghini A, Carlo Stella C
    Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma.
    Blood. 2023 Mar 10:blood.2022016590. doi: 10.1182/blood.2022016590.
    PubMed     Abstract available

  32. SANTORO A, Moskowitz AJ, Ferrari S, Carlo-Stella C, et al
    Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
    Blood. 2023 Mar 10:blood.2022017951. doi: 10.1182/blood.2022017951.

    Synthetic lethality in ATL.
    Blood. 2023;141:1096-1098.

  34. LEFEBVRE C, Szymanski G
    Extranodal presentation of a MYC/BCL6 double-hit lymphoma with 11q aberration in an older patient.
    Blood. 2023;141:1093.

  35. SPINNER MA, Sica RA, Tamaresis JS, Lu Y, et al
    Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
    Blood. 2023 Mar 1:blood.2022018827. doi: 10.1182/blood.2022018827.
    PubMed     Abstract available

    February 2023
  36. NEELAPU SS, Jacobson CA, Ghobadi A, Miklos DB, et al
    5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).
    Blood. 2023 Feb 23:blood.2022018893. doi: 10.1182/blood.2022018893.
    PubMed     Abstract available

  37. RODDIE C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, et al
    Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Blood. 2023 Feb 23:blood.2022018598. doi: 10.1182/blood.2022018598.
    PubMed     Abstract available

    Meet the Burkitts: a dark zone family.
    Blood. 2023;141:816-818.

    HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma.
    Blood. 2023 Feb 17:blood.2022019332. doi: 10.1182/blood.2022019332.
    PubMed     Abstract available

  40. RUAN J, Moskowitz AJ, Mehta-Shah N, Sokol L, et al
    Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.
    Blood. 2023 Feb 16:blood.2022018254. doi: 10.1182/blood.2022018254.
    PubMed     Abstract available

  41. CAIRO MS
    EBV: the virus that keeps on giving!
    Blood. 2023;141:689-691.

  42. KHODADOUST MS, Mou E, Kim YH
    Integrating novel agents into the treatment of advanced mycosis fungoides and Sezary syndrome.
    Blood. 2023;141:695-703.
    PubMed     Abstract available

  43. ELITZUR S, Vora A, Burkhardt B, Inaba H, et al
    EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.
    Blood. 2023;141:743-755.
    PubMed     Abstract available

  44. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.
    Blood. 2023;141:683.

  45. STEWART BJ, Fergie M, Young M, Jones C, et al
    Spatial and molecular profiling of the mononuclear phagocyte network in Classic Hodgkin lymphoma.
    Blood. 2023 Feb 7:blood.2022015575. doi: 10.1182/blood.2022015575.
    PubMed     Abstract available

  46. ALDERUCCIO JP, Reis IM, Koff JL, Larson MC, et al
    Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
    Blood. 2023 Feb 3:blood.2022019294. doi: 10.1182/blood.2022019294.

  47. PINA-OVIEDO S, Motwani P
    Composite ALK-negative anaplastic large-cell lymphoma and mantle cell lymphoma.
    Blood. 2023;141:556.

  48. KHODADOUST M, Silva O
    Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype.
    Blood. 2023;141:555.

  49. YOON SE, Kang W, Choi S, Park Y, et al
    The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.
    Blood. 2023 Feb 1:blood.2022018831. doi: 10.1182/blood.2022018831.
    PubMed     Abstract available

    January 2023

  50. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.
    Blood. 2023;141:437.

  51. JAEGER A, Gambheer SMM, Sun X, Chernyakov D, et al
    Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
    Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.
    PubMed     Abstract available

  52. YUAN CT, Chuang SS
    Effusion presentation of HHV-8-associated multicentric Castleman disease mimicking primary effusion lymphoma.
    Blood. 2023;141:320.

  53. NAHMOD KA, Vega F
    ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK.
    Blood. 2023;141:209.

    TOXic T-cell cytokines wreak havoc in CTCL skin.
    Blood. 2023;141:127-128.

  55. WHITTAKER S, Jones CL
    CD39-CD73-adenosine effects in Sezary syndrome.
    Blood. 2023;141:9-10.

  56. YAKYMIV Y, Marchisio S, Ortolan E, Bracci C, et al
    CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sezary syndrome.
    Blood. 2023;141:111-116.

    December 2022
  57. QIU L, Quesada AE
    Lymphoplasmacytic lymphoma with IgG paraprotein and extensive plasmacytic differentiation mimicking plasma cell neoplasm.
    Blood. 2022;140:2857.

  58. HORNA P, Otteson G, Shi M, Seheult JN, et al
    Improved semiautomated detection of TRBC-restricted Sezary cells unveils a spectrum of clonal cluster immunophenotypes.
    Blood. 2022;140:2852-2856.

  59. HARKER-MURRAY P, Mauz-Korholz C, Leblanc TM, Mascarin M, et al
    Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults.
    Blood. 2022 Dec 23:blood.2022017118. doi: 10.1182/blood.2022017118.
    PubMed     Abstract available

  60. AOKI T, Steidl C
    Novel insights into Hodgkin lymphoma biology by single cell analysis.
    Blood. 2022 Dec 22:blood.2022017147. doi: 10.1182/blood.2022017147.
    PubMed     Abstract available

  61. KIM DH, Thakral B
    False CD10 positivity in MALT lymphoma involving kidney.
    Blood. 2022;140:2760.

    Pola-R-CHP for DLBCL: cost-effective at first glance.
    Blood. 2022;140:2654-2655.

  63. ABRAMSON JS, Solomon SR, Arnason JE, Johnston PB, et al
    Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study.
    Blood. 2022 Dec 21:blood.2022018730. doi: 10.1182/blood.2022018730.
    PubMed     Abstract available

  64. JAFFE ES, Cook JR
    Core biopsy for lymphoma diagnosis? A needling prospect.
    Blood. 2022;140:2525-2527.

  65. FALINI B, Lazzi S
    Pediatric large B-cell lymphoma with 11q aberration.
    Blood. 2022;140:2644.

  66. FALINI B, Lazzi S
    Diffuse large B-cell lymphoma of the testis.
    Blood. 2022;140:2645.

    Post-CAR relapse in DLBCL: a fork in the road.
    Blood. 2022;140:2527-2529.

  68. Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2021;139(9):1266-1267.
    Blood. 2022;140:2646.

  69. DREVAL K, Boutros PC, Morin RD
    Minimal information for reporting a genomics experiment.
    Blood. 2022;140:2549-2555.
    PubMed     Abstract available

  70. KUUSANMAKI H, Dufva O, Vaha-Koskela M, Leppa AM, et al
    Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
    Blood. 2022 Dec 12:blood.2021011094. doi: 10.1182/blood.2021011094.
    PubMed     Abstract available

    A N(ew) MYC joins T-cell lymphomagenesis.
    Blood. 2022;140:2416-2417.

  72. RAHNAMA R, Bonifant CL
    Engineering builds multipotency for iPSC-NKs.
    Blood. 2022;140:2414-2416.

  73. MARTINES C, Chakraborty S, Vujovikj M, Gobessi S, et al
    Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
    Blood. 2022;140:2335-2347.
    PubMed     Abstract available

    November 2022
  74. GHOSH N
    Axi-cel in LBCL: fulfill two needs with one deed.
    Blood. 2022;140:2183-2185.

  75. DE LEVAL L, Alizadeh AA, Bergsagel PL, Campo E, et al
    Genomic profiling for clinical decision making in lymphoid neoplasms.
    Blood. 2022;140:2193-2227.
    PubMed     Abstract available

  76. WILKENS AB, Fulton EC, Pont MJ, Cole GO, et al
    NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
    Blood. 2022;140:2261-2275.
    PubMed     Abstract available

  77. THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Blood. 2022;140:2113-2126.
    PubMed     Abstract available

  78. DELAGE L, Lambert M, Bardel E, Kundlacz C, et al
    BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.
    Blood. 2022 Nov 14. pii: 487109. doi: 10.1182/blood.2022016943.
    PubMed     Abstract available

    A Tet-a-Tet in T follicular helper cell lymphoma.
    Blood. 2022;140:1919-1921.

  80. CHIBA M, Shimono J, Ishio T, Takei N, et al
    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Blood. 2022;140:1951-1963.
    PubMed     Abstract available

  81. FALCHI L, Vardhana SA, Salles GA
    Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities.
    Blood. 2022 Nov 2. pii: 486966. doi: 10.1182/blood.2021011994.
    PubMed     Abstract available

    October 2022
  82. RUSHTON CK, Dreval K, Morin RD
    Concerning data inconsistencies in Burkitt lymphoma genome study.
    Blood. 2022 Oct 27. pii: 486935. doi: 10.1182/blood.2022016505.

  83. ALDUAIJ W, Collinge BJ, Ben-Neriah S, Jiang A, et al
    Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population.
    Blood. 2022 Oct 27. pii: 486923. doi: 10.1182/blood.2022018248.
    PubMed     Abstract available

  84. DAVE SS
    Burkitt lymphoma genomic discovery studies, drivers and validation.
    Blood. 2022 Oct 27. pii: 486922. doi: 10.1182/blood.2022018865.

  85. RUAN J
    Claiming the mantle of the brain.
    Blood. 2022;140:1835-1836.

  86. SHARMA M, Fu MP, Lu HY, Sharma AA, et al
    Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
    Blood. 2022;140:1858-1874.
    PubMed     Abstract available

  87. FRONTZEK F, Lenz G
    Tackling ALK-positive LBCL.
    Blood. 2022;140:1751-1752.

  88. ZHAO L, Li S, Wei X, Qi X, et al
    A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
    Blood. 2022;140:1790-1802.
    PubMed     Abstract available

  89. THOMAS N, Dreval K, Gerhard DS, Hilton LK, et al
    Blood. 2022 Oct 6. pii: 486739. doi: 10.1182/blood.2022016534.
    PubMed     Abstract available

    September 2022
  90. IZUTSU K, Makita S, Nosaka K, Yoshimitsu M, et al
    An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
    Blood. 2022 Sep 23. pii: 486703. doi: 10.1182/blood.2022016862.
    PubMed     Abstract available

  91. BLOMBERY P, Cheah CY
    Predicting the future in MCL with MRD.
    Blood. 2022;140:1332-1333.

  92. GLUUD M, Pallesen EMH, Buus TB, Gjerdrum LMR, et al
    Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signalling in cutaneous T-cell lymphoma.
    Blood. 2022 Sep 19. pii: 486665. doi: 10.1182/blood.2022016690.
    PubMed     Abstract available

  93. DI BLASI R, Le Gouill S, Bachy E, Cartron G, et al
    Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.
    Blood. 2022 Sep 19. pii: 486662. doi: 10.1182/blood.2022016945.
    PubMed     Abstract available

  94. CAMPO E, Jaffe ES, Cook JR, Quintanilla-Martinez L, et al
    The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
    Blood. 2022;140:1229-1253.
    PubMed     Abstract available

  95. HEREK TA, Bouska A, Lone W, Sharma S, et al
    DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.
    Blood. 2022;140:1278-1290.
    PubMed     Abstract available

  96. HEGAZY SE, Bailey NG
    Progression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma.
    Blood. 2022;140:1182.

    Radiotherapy is here to stay.
    Blood. 2022;140:1053-1054.

  98. WEN R, Wang D
    MCD-DLBCL arises from germinal center B cells.
    Blood. 2022;140:1058-1059.

  99. PHILIPP N, Kazerani M, Nicholls A, Vick B, et al
    T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Blood. 2022;140:1104-1118.
    PubMed     Abstract available

  100. VOSE JM
    To transplant or not to transplant: that is the question in PTCL.
    Blood. 2022;140:936-937.

  101. BRINK M, Meeuwes FO, van der Poel MWM, Kersten MJ, et al
    Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
    Blood. 2022;140:1009-1019.
    PubMed     Abstract available

    August 2022
  102. GASIOROWSKI R, Trotman J
    CAR-T for follicular lymphoma: are we good to go?
    Blood. 2022;140:799-800.

  103. VENKATARAMAN G, Alikhan MB
    Numerous B cells in a mediastinal mass, but not a B-cell lymphoma.
    Blood. 2022;140:932.

  104. Atabay EK, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022;139(5):717-731.
    Blood. 2022;140:794.

  105. OZKAYA N, Jaffe ES
    Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression.
    Blood. 2022;140:793.

  106. FLERLAGE JE, Myers JR, Maciaszek JL, Oak N, et al
    Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.
    Blood. 2022 Aug 17. pii: 486283. doi: 10.1182/blood.2022016056.
    PubMed     Abstract available

  107. VANDEN BEMPT M, Debackere K, Demeyer S, Van Thillo Q, et al
    Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.
    Blood. 2022 Aug 12. pii: 486219. doi: 10.1182/blood.2022016428.
    PubMed     Abstract available

  108. HESLOP HE
    Tumor-intrinsic causes of CAR-T failure.
    Blood. 2022;140:414-415.

  109. SHALABI H, Qin H, Su A, Yates B, et al
    CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Blood. 2022;140:451-463.
    PubMed     Abstract available

  110. FUJISAWA M, Nguyen TB, Abe Y, Suehara Y, et al
    Clonal germinal center B cells function as a niche for T-cell lymphoma.
    Blood. 2022 Aug 3. pii: 486092. doi: 10.1182/blood.2022015451.
    PubMed     Abstract available

  111. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    PubMed     Abstract available

  112. KAMBHAMPATI S, Saumoy M, Schneider Y, Serrao S, et al
    Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2022 Aug 1. pii: 486082. doi: 10.1182/blood.2022016747.
    PubMed     Abstract available

    July 2022
  113. CRAIG A, Wen KW
    EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.
    Blood. 2022;140:406.

  114. DARNELL EP, Jacobson CA
    German CARs keeping pace.
    Blood. 2022;140:296-298.

    Reed-Sternberg-like cells in a case of follicular lymphoma.
    Blood. 2022;140:290.

  116. ELSAWY M, Chavez JC, Avivi I, Larouche JF, et al
    Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
    Blood. 2022 Jul 15. pii: 485937. doi: 10.1182/blood.2022015478.
    PubMed     Abstract available

  117. SOUMERAI JD, Rosenthal AC, Harkins SK, Duffy J, et al
    Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
    Blood. 2022 Jul 8. pii: 485824. doi: 10.1182/blood.2022015443.
    PubMed     Abstract available

  118. SYRYKH C, Chaouat C, Poullot E, Amara N, et al
    Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.
    Blood. 2022 Jul 7. pii: 485815. doi: 10.1182/blood.2022015520.
    PubMed     Abstract available

  119. ZHOU L, Wang C
    A unique report of breast intravascular NK/T-cell lymphoma mimicking breast carcinoma.
    Blood. 2022;140:78.

  120. BUENO C, Barrera S, Bataller A, Ortiz-Maldonado V, et al
    CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
    Blood. 2022;140:38-44.
    PubMed     Abstract available

  121. RUSCONI C, Cheah CY, Eyre TA, Tucker DL, et al
    Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse.
    Blood. 2022 Jul 5. pii: 485785. doi: 10.1182/blood.2022015560.
    PubMed     Abstract available

    June 2022
    Mechanisms of resistance to mogamulizumab.
    Blood. 2022;139:3674-3676.

  123. STRATI P
    CAR T-cell therapy: which product for which patient?
    Blood. 2022;139:3673-3674.

  124. GAUTHIER J, Gazeau N, Hirayama AV, Hill JA, et al
    Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
    Blood. 2022;139:3722-3731.
    PubMed     Abstract available

  125. PAREKH A, Keller FG, McCarten KM, Kessel S, et al
    Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.
    Blood. 2022 Jun 28. pii: 485708. doi: 10.1182/blood.2022016098.
    PubMed     Abstract available

  126. PINDZOLA GM, Razzaghi R, Tavory RN, Nguyen HT, et al
    Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.
    Blood. 2022 Jun 27. pii: 485703. doi: 10.1182/blood.2022015926.
    PubMed     Abstract available

  127. FERRERO S, Grimaldi D, Genuardi E, Drandi D, et al
    Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.
    Blood. 2022 Jun 23. pii: 485688. doi: 10.1182/blood.2021014270.
    PubMed     Abstract available

    Smart salvage treatment for Hodgkin lymphoma.
    Blood. 2022;139:3563-3564.

  129. IZQUIERDO E, Vorholt D, Blakemore S, Sackey B, et al
    Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.
    Blood. 2022;139:3617-3629.
    PubMed     Abstract available

  130. BACKER K, Wang HY
    Florid reactive follicular hyperplasia with exuberant HHV8 infection.
    Blood. 2022;139:3558.

  131. KAMBHAMPATI S, Saumoy M, Schneider Y, Pak S, et al
    Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma.
    Blood. 2022 Jun 14. pii: 485545. doi: 10.1182/blood.2022016624.
    PubMed     Abstract available

  132. GHIONE P, Palomba ML, Patel A, Bobillo S, et al
    Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Blood. 2022 Jun 9. pii: 485518. doi: 10.1182/blood.2021014375.
    PubMed     Abstract available

  133. PETERSON JM, Lyapichev KA
    Extranodal natural killer/T-cell lymphoma of the palate.
    Blood. 2022;139:3450.

  134. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed     Abstract available

    May 2022
  135. HAMNVAG HM, Velankar M
    Hemophagocytic lymphohistiocytosis with multiple possible etiologies including rare primary bone marrow lymphoma.
    Blood. 2022;139:3226.

  136. KAMDAR M
    A cauldron of choices.
    Blood. 2022;139:3103-3104.

  137. CERHAN JR
    A (modifiable) way to better Hodgkin lymphoma survivorship?
    Blood. 2022;139:3004-3005.

  138. CALABRETTA E, Hamadani M, Carlo-Stella C
    Blood. 2022 May 17. pii: 485279. doi: 10.1182/blood.2021014663.
    PubMed     Abstract available

  139. ALI A, Goy A, Dunleavy K
    CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights.
    Blood. 2022 May 13. pii: 485238. doi: 10.1182/blood.2022016226.
    PubMed     Abstract available

  140. ATANACKOVIC D, Luetkens T, Omili D, Iraguha T, et al
    Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART.
    Blood. 2022 May 10. pii: 485211. doi: 10.1182/blood.2022016175.

  141. CHERNG HJ, Sun R, Sugg B, Irwin R, et al
    Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma.
    Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
    PubMed     Abstract available

  142. NAKAMURA A, Grossman S, Song K, Xega K, et al
    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Blood. 2022;139:2770-2781.
    PubMed     Abstract available

  143. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    PubMed     Abstract available

    April 2022
  144. TADROS S, Jaffe ES
    A novel case of gamma-delta T-cell lymphoma expressing CD4, recapitulating a stage of gamma-delta T-cell development.
    Blood. 2022;139:2725.

  145. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.
    Blood. 2022;139:2726.

  146. SONIGO G, Bozonnat A, Dumont M, Thonnart N, et al
    Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
    Blood. 2022;139:2712-2716.

  147. JAIN MD, Ziccheddu B, Coughlin CA, Faramand RG, et al
    Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
    Blood. 2022 Apr 27. pii: 485092. doi: 10.1182/blood.2021015008.
    PubMed     Abstract available

    CNS prophylaxis in DLBCL: first do no harm.
    Blood. 2022;139:2420-2421.

  149. WILSON MR, Eyre TA, Kirkwood AA, Wong Doo N, et al
    Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Blood. 2022;139:2499-2511.
    PubMed     Abstract available

  150. BEYGI S, Duran GE, Fernandez-Pol S, Rook AH, et al
    Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
    Blood. 2022 Apr 18. pii: 484969. doi: 10.1182/blood.2021014468.
    PubMed     Abstract available

  151. CHONG EA, Schuster SJ
    No CNS sanctuary for lymphoma from CAR T.
    Blood. 2022;139:2261-2263.

    Chemotherapy-free regimens in frontline follicular lymphoma.
    Blood. 2022;139:2263-2264.

    Turning up the heat on salivary gland MALT lymphoma.
    Blood. 2022;139:2094-2096.

    March 2022
  154. LIANG HC, Elenitoba-Johnson KSJ
    Targeting IMiD-resistant T-cell lymphoma.
    Blood. 2022;139:1932-1933.

  155. WU W, Nelson GM, Koch R, Donovan KA, et al
    Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
    Blood. 2022;139:2024-2037.
    PubMed     Abstract available

  156. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    PubMed     Abstract available

  157. KURTZ DM
    The many facets of liquid biopsies in lymphoma.
    Blood. 2022;139:1780-1781.

  158. DE MASSON A, Darbord D, Dobos G, Boisson M, et al
    Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    Blood. 2022;139:1820-1832.
    PubMed     Abstract available

  159. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    PubMed     Abstract available

  160. MEI MG, Lee HJ, Palmer J, Chen RW, et al
    Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).
    Blood. 2022 Mar 22. pii: 484451. doi: 10.1182/blood.2022015423.
    PubMed     Abstract available

  161. BETHGE WA, Martus P, Schmitt M, Holtick U, et al
    GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
    Blood. 2022 Mar 22. pii: 484450. doi: 10.1182/blood.2021015209.
    PubMed     Abstract available

  162. SONG Y, Zhou K, Zou DH, Zhou J, et al
    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
    Blood. 2022 Mar 18. pii: 484435. doi: 10.1182/blood.2021014162.
    PubMed     Abstract available

    POD24 in follicular lymphoma: time to be "wise".
    Blood. 2022;139:1609-1610.

  164. Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021;137(1):39-48.
    Blood. 2022;139:1772.

  165. AYPAR U, Ewalt MD
    A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration.
    Blood. 2022;139:1771.

  166. CASULO C, Dixon JG, Le-Rademacher J, Hoster E, et al
    Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood. 2022;139:1684-1693.
    PubMed     Abstract available

  167. PORPACZY E, Jager U
    How I manage autoimmune cytopenias in patients with lymphoid cancer.
    Blood. 2022;139:1479-1488.
    PubMed     Abstract available

  168. NAYAK L, Batchelor TT
    How I treat neurologic complications in patients with lymphoid cancer.
    Blood. 2022;139:1469-1478.
    PubMed     Abstract available

  169. WESTIN JR, Sehn L
    CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?
    Blood. 2022 Mar 3. pii: 484263. doi: 10.1182/blood.2022015789.
    PubMed     Abstract available

  170. LULLA PD
    CAR T cells and autologous transplantation can coexist for DLBCL.
    Blood. 2022;139:1266-1267.

  171. SHADMAN M, Pasquini M, Ahn KW, Chen Y, et al
    Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
    Blood. 2022;139:1330-1339.
    PubMed     Abstract available

    February 2022

  172. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2022;139:1256.

  173. MARTIN P, Bartlett NL, Chavez JC, Reagan JL, et al
    Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Blood. 2022;139:1147-1159.
    PubMed     Abstract available

  174. SHAH NN, Harrington AM
    Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy.
    Blood. 2022;139:1116.

  175. CHONG EA, Alanio C, Svoboda J, Nasta SD, et al
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Blood. 2022;139:1026-1038.
    PubMed     Abstract available

  176. FRIGAULT MJ, Dietrich J, Gallagher KME, Roschewski MJ, et al
    Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
    Blood. 2022 Feb 15. pii: 484042. doi: 10.1182/blood.2021014738.
    PubMed     Abstract available

  177. KIM DH, Vega F
    Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
    Blood. 2022;139:951.

  178. CAO X, Wang Y, Zhang W, Zhong X, et al
    Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression.
    Blood. 2022 Feb 8. pii: 483887. doi: 10.1182/blood.2021013901.
    PubMed     Abstract available

  179. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.

  180. YU YT, Chang KC
    Burkitt-like lymphoma with 11q aberrations: a highly apoptotic and high-grade lymphoma.
    Blood. 2022;139:797.

  181. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    PubMed     Abstract available

    January 2022
  182. KLEIN U
    Metabolic path toward TCF3 inactivation in Burkitt lymphoma.
    Blood. 2022;139:475-476.

  183. TARIQ H, Zahra U
    Fibrin-associated diffuse large B-cell lymphoma with aberrant CD4 expression.
    Blood. 2022;139:635.

  184. WILKE AC, Doebele C, Zindel A, Lee KS, et al
    SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Blood. 2022;139:538-553.
    PubMed     Abstract available

  185. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.

  186. SCHMITZ N, Frontzek F
    CNS prophylaxis in DLBCL: time to say goodbye?
    Blood. 2022;139:315-317.

  187. ORELLANA-NOIA VM, Reed DR, McCook AA, Sen JM, et al
    Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Blood. 2022;139:413-423.
    PubMed     Abstract available

    PET imaging: back in the game for gastric EMZL?
    Blood. 2022;139:154-155.

  189. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    PubMed     Abstract available

  190. SHEN Y, Zhou J, Nie K, Cheng S, et al
    Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.
    Blood. 2022;139:73-86.
    PubMed     Abstract available

  191. ANDRADES DELGADO A, Alvarez-Perez JC, Patino-Mercau JR, Cuadros M, et al
    Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes.
    Blood. 2022 Jan 5. pii: 483332. doi: 10.1182/blood.2021011708.

    December 2021
  192. MOSKOWITZ AJ, Ghione P, Jacobsen E, Ruan J, et al
    A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Blood. 2021;138:2828-2837.
    PubMed     Abstract available

  193. LIU H, Hu S
    EBV+ ALK+ large B-cell lymphoma.
    Blood. 2021;138:2741.

  194. BACHY E, Houot R, Feugier P, Bouabdallah K, et al
    Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.
    Blood. 2021 Dec 22. pii: 483234. doi: 10.1182/blood.2021013526.
    PubMed     Abstract available

  195. HAWKES EA, Barraclough A, Sehn LH
    Limited-stage Diffuse Large B-cell Lymphoma.
    Blood. 2021 Dec 21. pii: 483215. doi: 10.1182/blood.2021013998.
    PubMed     Abstract available

  196. MERIRANTA L, Alkodsi A, Pasanen A, Lepisto M, et al
    Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Blood. 2021 Dec 21. pii: 483214. doi: 10.1182/blood.2021012852.
    PubMed     Abstract available

  197. JONAK C, Brunner PM
    Blood will tell: profiling Sezary syndrome.
    Blood. 2021;138:2450-2451.

  198. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.

  199. NAJIDH S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, et al
    Improved Sezary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome.
    Blood. 2021;138:2539-2554.
    PubMed     Abstract available

  200. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    PubMed     Abstract available

  201. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    PubMed     Abstract available

  202. BUUS TB, Koralov SB
    Oncogenic fusions JAK up CD8+ cytotoxic CTCL.
    Blood. 2021;138:2311-2312.

  203. LEE K, Evans MG, Yang L, Ng S, et al
    Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
    Blood. 2021;138:2435-2440.

  204. ALCANTARA M, Houillier C, Blonski M, Rubio MT, et al
    CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network.
    Blood. 2021 Dec 6. pii: 482903. doi: 10.1182/blood.2021012932.

  205. WILLIAMS AM, Mirzaei Salehabadi S, Xing M, Phillips NS, et al
    Modifiable Risk Factors for Neurocognitive and Psychosocial Problems After Hodgkin Lymphoma.
    Blood. 2021 Dec 3. pii: 482888. doi: 10.1182/blood.2021013167.
    PubMed     Abstract available

  206. WANG Z, Guo R, Trudeau SJ, Wolinsky E, et al
    CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.
    Blood. 2021;138:2216-2230.
    PubMed     Abstract available

    November 2021
  207. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available

  208. YANG G, Wang J, Tan L, Munshi M, et al
    The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Blood. 2021;138:1966-1979.
    PubMed     Abstract available

  209. WARD J, Berrien-Elliott MM, Gomez F, Luo J, et al
    Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2021 Nov 15. pii: 477971. doi: 10.1182/blood.2021011894.
    PubMed     Abstract available

  210. FANG H, Xu J
    Peripheral T-cell lymphoma with blastoid morphology and aberrant expression of multiple B-cell antigens.
    Blood. 2021;138:1906.

  211. ZHANG J, Lucas D
    A young microenvironment promotes B-ALL in mice.
    Blood. 2021;138:1789-1790.

  212. OLSEN EA, Whittaker S, Willemze R, Pinter-Brown L, et al
    Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
    Blood. 2021 Nov 10. pii: 477944. doi: 10.1182/blood.2021012057.
    PubMed     Abstract available

    October 2021
  213. OKWAN-DUODU D, Huang Q
    Primary splenic Burkitt-like lymphoma with 11q aberration.
    Blood. 2021;138:1642.

  214. KUPPERS R
    Sugar-modified B-cell receptors in DLBCL.
    Blood. 2021;138:1512-1514.

  215. CHIODIN G, Allen JD, Bryant DJ, Rock P, et al
    Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
    Blood. 2021;138:1570-1582.
    PubMed     Abstract available

  216. SCHAFF LR, Grommes C
    Primary Central Nervous System Lymphoma.
    Blood. 2021 Oct 26. pii: S0006-4971(21)01788-2. doi: 10.1182/blood.2020008377.
    PubMed     Abstract available

  217. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available

  218. EYRE TA, Cheah CY, Wang ML
    Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Blood. 2021 Oct 22. pii: S0006-4971(21)01781-X. doi: 10.1182/blood.2021013326.
    PubMed     Abstract available

  219. WILSON MH, Gottschalk S
    Expect the unexpected: piggyBac and lymphoma.
    Blood. 2021;138:1379-1380.

  220. GROS A, Merlio JP
    Single-cell trajectories in Sezary syndrome.
    Blood. 2021;138:1384-1386.

  221. LIEBERS N, Speer C, Benning L, Bruch PM, et al
    Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.
    Blood. 2021 Oct 20. pii: 477393. doi: 10.1182/blood.2021013445.

  222. JOHNSTON RL, Mottok A, Chan FC, Jiang A, et al
    Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
    Blood. 2021 Oct 18. pii: 477371. doi: 10.1182/blood.2021011941.
    PubMed     Abstract available

  223. KARACA ATABAY E, Mecca C, Wang Q, Ambrogio C, et al
    Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Blood. 2021 Oct 17. pii: 477348. doi: 10.1182/blood.2020008136.
    PubMed     Abstract available

  224. BONFIGLIO F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, et al
    Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.
    Blood. 2021 Oct 15. pii: 477330. doi: 10.1182/blood.2021012386.
    PubMed     Abstract available

    PD-1 loss and T-cell exhaustion in CTCL tumoral T cells.
    Blood. 2021;138:1201-1203.

  226. PARK J, Daniels J, Wartewig T, Ringbloom KG, et al
    Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.
    Blood. 2021;138:1225-1236.
    PubMed     Abstract available

    September 2021
  227. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.

  228. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    PubMed     Abstract available

  229. MINDERMAN M, Amir A, Kraan W, Schilder-Tol EJM, et al
    Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
    Blood. 2021;138:1194-1197.

  230. LIU F, Gao Y, Xu B, Xiong S, et al
    PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.
    Blood. 2021 Sep 28. pii: 477066. doi: 10.1182/blood.2021012091.
    PubMed     Abstract available

  231. TENSEN CP, Quint KD, Vermeer MH
    Genetic and epigenetic insights into cutaneous T-cell lymphoma.
    Blood. 2021 Sep 27. pii: 477053. doi: 10.1182/blood.2019004256.
    PubMed     Abstract available

    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.

  233. GAO J, Sidiropoulou E, Walker I, Krupka JA, et al
    SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence.
    Blood. 2021;138:959-964.
    PubMed     Abstract available

  234. MAYERHOEFER M, Raderer M, Lamm W, Weber M, et al
    CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication.
    Blood. 2021 Sep 15. pii: 476918. doi: 10.1182/blood.2021013239.
    PubMed     Abstract available

  235. OLSZEWSKI A, Kurt H, Evens AM
    Defining and Treating High-grade B-cell lymphoma, NOS.
    Blood. 2021 Sep 15. pii: 476913. doi: 10.1182/blood.2020008374.
    PubMed     Abstract available

  236. DANIELS J, Choi J
    BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product-derived CAR-T cell lymphomas.
    Blood. 2021 Sep 9. pii: 476840. doi: 10.1182/blood.2021012641.

  237. SAVAGE KJ
    Primary mediastinal Large B-cell Lymphoma.
    Blood. 2021 Sep 9. pii: 476814. doi: 10.1182/blood.2020008376.
    PubMed     Abstract available

  238. GERMANS SK, Chen M
    Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
    Blood. 2021;138:912.

  239. SCHMITT A, Xu W, Bucher P, Grimm M, et al
    Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL.
    Blood. 2021;138:871-884.
    PubMed     Abstract available

  240. SCHMIDT RA, Lee AY
    How I treat and prevent venous thrombotic complications in patients with lymphoma.
    Blood. 2021 Sep 3. pii: 476786. doi: 10.1182/blood.2019003689.
    PubMed     Abstract available

  241. CARBONE A, Vaccher E, Gloghini A
    Hematological cancers in individuals infected by HIV.
    Blood. 2021 Sep 1. pii: 476746. doi: 10.1182/blood.2020005469.
    PubMed     Abstract available

    August 2021
    "Allo" from the (marginal) zone.
    Blood. 2021;138:595-596.

  243. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.

  244. CHOI Y, Diefenbach C
    Expanding landscape for relapsed Hodgkin lymphoma.
    Blood. 2021;138:421-422.

  245. GALINDO-CAMPOS MA, Lutfi N, Bonnin S, Martinez C, et al
    Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
    Blood. 2021 Aug 6. pii: 476527. doi: 10.1182/blood.2021012805.
    PubMed     Abstract available

    Epigenetic balance in DLBCL.
    Blood. 2021;138:355-356.

  247. HEWARD J, Konali L, D'Avola A, Close K, et al
    KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
    Blood. 2021;138:370-381.
    PubMed     Abstract available

    July 2021
  248. XU W, Berning P, Lenz G
    Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 28. pii: 476467. doi: 10.1182/blood.2020006784.
    PubMed     Abstract available

  249. ADVANI RH, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
    Blood. 2021;138:213-220.
    PubMed     Abstract available

  250. DUNS G, Vigano E, Ennishi D, Sarkozy C, et al
    Characterization of DLBCL with a PMBL gene expression signature.
    Blood. 2021;138:136-148.
    PubMed     Abstract available

  251. TROTMAN J, Pettitt AR
    Is it time for PET-guided therapy in follicular lymphoma.
    Blood. 2021 Jul 14. pii: 476386. doi: 10.1182/blood.2020008243.
    PubMed     Abstract available

  252. HERRERA A, Cheng A, Mimitou EP, Seffens A, et al
    Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures.
    Blood. 2021 Jul 7. pii: 476325. doi: 10.1182/blood.2020009346.
    PubMed     Abstract available

  253. ELUARD B, Nuan-Aliman S, Faumont N, Collares D, et al
    The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 7. pii: 476326. doi: 10.1182/blood.2020010039.
    PubMed     Abstract available

  254. BURKE GAA
    Brentuximab vedotin: frontline help in ALCL.
    Blood. 2021;137:3581-3582.

  255. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Blood. 2021;137:3595-3603.
    PubMed     Abstract available

    June 2021
  256. BALSAS P, Veloza L, Clot G, Sureda-Gomez M, et al
    SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
    Blood. 2021 Jun 29. pii: 476270. doi: 10.1182/blood.2020010527.
    PubMed     Abstract available

  257. GHIONE P, Gu JJ, Attwood K, Torka P, et al
    Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.
    Blood. 2021 Jun 29. pii: 476275. doi: 10.1182/blood.2021012443.

  258. REJESKI K, Perez Perez A, Sesques P, Hoster E, et al
    CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
    Blood. 2021 Jun 24. pii: 476241. doi: 10.1182/blood.2020010543.
    PubMed     Abstract available

  259. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.

  260. PEYRON JF
    Blocking RiBi to suppress MYC lymphomagenesis.
    Blood. 2021;137:3316-3318.

    Mantle cell lymphoma continues to surprise, and inform!
    Blood. 2021;137:3158-3160.

  262. PASTORET C, Desmots F, Drillet G, Le Gallou S, et al
    Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
    Blood. 2021;137:3237-3250.
    PubMed     Abstract available

  263. KORONA B, Korona D, Zhao W, Wotherspoon A, et al
    GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
    Blood. 2021 Jun 4. pii: 476070. doi: 10.1182/blood.2020010495.
    PubMed     Abstract available

  264. CAI J, Qing X
    Splenic marginal zone lymphoma with increased prolymphocytes.
    Blood. 2021;137:3150.

    May 2021
  265. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.

  266. PLAKS V, Rossi JM, Chou J, Wang L, et al
    CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Blood. 2021 May 27. pii: 476038. doi: 10.1182/blood.2021010930.
    PubMed     Abstract available

  267. SONG S, Cao C, Choukrallah MA, Tang F, et al
    OBF1 and Oct factors control the germinal center transcriptional program.
    Blood. 2021;137:2920-2934.
    PubMed     Abstract available

  268. BOIKO S, Proia T, San Martin M, Gregory GP, et al
    Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Blood. 2021;137:2947-2957.
    PubMed     Abstract available

  269. SOUSSAIN C, Malaise D, Cassoux N
    Primary vitreoretinal lymphoma: A diagnostic and management challenge.
    Blood. 2021 May 25. pii: 476013. doi: 10.1182/blood.2020008235.
    PubMed     Abstract available

  270. MAAS-BAUER K, Lohmeyer JK, Hirai T, Lopes Ramos T, et al
    Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.
    Blood. 2021 May 25. pii: 476015. doi: 10.1182/blood.2021010887.
    PubMed     Abstract available

  271. REIMANN M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, et al
    Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Blood. 2021;137:2785-2799.
    PubMed     Abstract available

  272. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available

    A new warhead in lymphoma therapy?
    Blood. 2021;137:2568-2570.

  274. VOSE JM
    Outcomes for PTCL: which pathway to success?
    Blood. 2021;137:2570-2571.

  275. SCHMITZ N, Truemper L, Bouabdallah K, Ziepert M, et al
    A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Blood. 2021;137:2646-2656.
    PubMed     Abstract available

  276. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available

  277. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  278. ZHAO Y, Wang E
    An effusion-based presentation of ALK- anaplastic large cell lymphoma.
    Blood. 2021;137:2563.

  279. MAMLOUK O, Nair R, Iyer SP, Edwards A, et al
    Safety of CAR T-cell therapy in kidney transplant recipients.
    Blood. 2021;137:2558-2562.

    April 2021
  280. DAVIES A
    DLBCL outcomes: much ventured, much GAINED.
    Blood. 2021;137:2277-2278.

  281. LE GOUILL S, Ghesquieres H, Oberic L, Morschhauser F, et al
    Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
    Blood. 2021;137:2307-2320.
    PubMed     Abstract available

  282. EPPERLA N, Herrera AF
    How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.
    Blood. 2021 Apr 22. pii: 475828. doi: 10.1182/blood.2020007900.
    PubMed     Abstract available

  283. BLOMBERY P, Lade S
    Defining double-hit lymphoma in the clinic.
    Blood. 2021;137:2132-2133.

  284. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.

  285. FALCHI L, Ma H, Klein S, Lue JK, et al
    Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Blood. 2021;137:2161-2170.
    PubMed     Abstract available

  286. COLLINGE B, Ben-Neriah S, Chong L, Boyle M, et al
    The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.
    Blood. 2021;137:2196-2208.
    PubMed     Abstract available

  287. BALA TANNAN N, Manzari MT, Herviou L, Da Silva Ferreira M, et al
    Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
    Blood. 2021;137:2057-2069.
    PubMed     Abstract available

  288. SEWASTIANIK T, Straubhaar JR, Zhao JJ, Samur MK, et al
    miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
    Blood. 2021;137:1905-1919.
    PubMed     Abstract available

  289. ADVANI R, Moskowitz AJ, Bartlett NL, Vose J, et al
    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.
    PubMed     Abstract available

  290. CHIHARA D, Dores G, Flowers C, Morton LM, et al
    The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood. 2021 Apr 1. pii: 475679. doi: 10.1182/blood.2020010497.
    PubMed     Abstract available

  291. CAMPO E, Jaffe ES
    Taking gray zone lymphomas out of the shadows.
    Blood. 2021;137:1703-1704.

    March 2021
  292. YU X, Li W, Deng Q, Liu H, et al
    MYD88 L265P elicits mutation-specific ubiquitination to drive NF-kappaB activation and lymphomagenesis.
    Blood. 2021;137:1615-1627.
    PubMed     Abstract available

  293. HAN H, Fan G, Song S, Jiang Y, et al
    piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
    Blood. 2021;137:1603-1614.
    PubMed     Abstract available

  294. SHAH NN, Ahn KW, Litovich C, He Y, et al
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
    Blood. 2021;137:1416-1423.
    PubMed     Abstract available

  295. PIGNARRE A, Chatonnet F, Caron G, Haas M, et al
    Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.
    Blood. 2021;137:1166-1180.
    PubMed     Abstract available

    February 2021
    CNS relapse in DLBCL: a calculable risk?
    Blood. 2021;137:1011-1012.

  297. TRUJILLO JA, Godfrey J, Hu Y, Huang J, et al
    Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Blood. 2021 Feb 24. pii: 475347. doi: 10.1182/blood.2020009148.

  298. DUMONTET E, Pangault C, Roulois D, Desoteux M, et al
    Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.
    Blood. 2021 Feb 24. pii: 475345. doi: 10.1182/blood.2020008791.
    PubMed     Abstract available

    Building on BTK inhibition in MCL.
    Blood. 2021;137:861-862.

  300. WIRTH A, Mikhaeel NG
    PET response-guided radiotherapy for advanced DLBCL?
    Blood. 2021;137:866-867.

  301. RULAND J
    Synergy of MALT1 and mTOR inhibition in DLBCL.
    Blood. 2021;137:724-725.

  302. VITOLO U, Novo M
    Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
    Blood. 2021;137:577-579.

  303. CASULO C
    Checkpoint blockade in FL: eluding the king.
    Blood. 2021;137:581-582.

  304. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  305. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  306. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    PubMed     Abstract available

    January 2021
  307. ABEYKOON JP, Wu X, Nowakowski KE, Dasari S, et al
    Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Blood. 2021;137:513-523.
    PubMed     Abstract available

  308. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  309. LOSSOS IS
    Stage I DLBCL: extranodal may mean extra radiation.
    Blood. 2021;137:3-5.

    December 2020
  310. FUKUMOTO K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, et al
    VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Blood. 2020;136:3018-3032.
    PubMed     Abstract available

    November 2020
  311. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available

  312. VENTURUTTI L, Melnick AM
    The dangers of deja vu: memory B cells as the cells of origin of ABC-DLBCLs.
    Blood. 2020;136:2263-2274.
    PubMed     Abstract available

  313. GANG M, Marin ND, Wong P, Neal CC, et al
    CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Blood. 2020;136:2308-2318.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.